字号·· | 护眼
华盛顿邮报

首款能延缓阿尔茨海默病病情的药丸可能来自一个意想不到的地方The first pill to slow Alzheimer’s could come from an unexpected place

点「原文对照」整页切到原文,或双击某段只看那段的原文。

(iStock图片)(iStock)

波士顿——阿尔茨海默病药物研究充斥着失败。但本周,临床医生带来了一些出乎意料的积极消息,这归功于一款针对大脑疾病重新开发、类似于伟哥(Viagra)的药丸。

A drug that is sold in South Korea for erectile dysfunction stemmed mental decline in a year-long global trial of more than 1,500 people. BOSTON — Alzheimer’s drug research is littered with failures. But this week, clinicians delivered some unexpectedly positive news, courtesy of a Viagra-like pill that has been repurposed for the brain disease.

这种药物已在韩国以Mvix的名义销售用于治疗勃起功能障碍,在一项针对1500多名早期阿尔茨海默病患者、为期一年的全球试验中,它延缓了精神衰退——但仅限于那些当时没有服用其他痴呆症药物的患者。

The drug, already sold as Mvix in South Korea for erectile dysfunction, slowed mental decline in a year-long global trial of more than 1,500 people with early Alzheimer’s — but only in those who weren’t already taking other dementia drugs.

对于这部分占研究对象约40%的患者来说,与假药相比,低剂量的Mvix将病情恶化速度减缓了近三分之一。这一衡量标准是基于对患者及其照顾者关于记忆、判断力和处理日常生活能力进行的访谈。

For those patients, who made up about 40 percent of the study population, a lower-dose version of Mvix eased the disease’s march by nearly a third compared with a dummy pill. The measure is based on interviews with patients and their caregivers about memory, judgment and the ability to handle daily life.

换句话说,根据该公司的估计,一年后,服用该药的患者的病情大约处于安慰剂组在大约3个半月前所处的水平。如果这种效果持续下去,随着每年治疗的进行,争取到的时间可能会不断增加。

In other words, after a year, people on the drug were roughly where the placebo group had been about 3½ months earlier, according to the company’s estimate. If the effect holds, the time saved could keep growing with each year of treatment.

不过,试验的其余部分呈现了不同的情况。在另外60%的受试者中——即那些已经在服用标准药物来控制记忆力减退和神志不清等症状的人群——该药几乎没有显示出益处。因此,在整个受试群体中,这种效果消失了。

The rest of the trial told a different story, though. In the other 60 percent of subjects — people who were already taking standard medications to manage symptoms such as memory loss and confusion — the drug showed little to no benefit. As a result, across the full group, the effect disappeared.

尽管情况喜忧参半,但该试验的发起方表示这一结果取得了成功。正在开发该药用于治疗阿尔茨海默病的韩国公司AriBio此前已明确表示,它将从两个方面来评估结果:全体受试者以及未服用其他痴呆症药物的人群。任何一个群组取得成功,都将被视为达到了该研究的主要目标。

Despite the mixed picture, the trial’s sponsor says the outcome is a success. AriBio, the South Korean company developing the drug for Alzheimer’s, had specified in advance that it would judge the results two ways: in everyone and in people not taking other dementia medicines. A win in either group would then count as meeting the study’s main goal.

AriBio表示,它计划与美国食品药品监督管理局讨论,这些数据是否可以独立支撑申请,或者该机构是否会首先要求进行另一项试验。

AriBio said it plans to discuss with the FDA whether the data can stand on their own or whether the agency will want another trial first.

伦敦大学圣乔治大学城(City St George’s, University of London)神经科学家阿蒂库斯·海因斯沃思(Atticus Hainsworth)等外部专家持谨慎乐观态度。海因斯沃思并未参与这项阿尔茨海默病研究,但他正在评估AriBio的这种药物用于另一种影响小血管的脑部疾病的效果,该病是中风和痴呆症的常见病因。他说,就目前而言,在未服用其他痴呆症药物的人群中,证据“在我看来相当不错”。

Outside experts such as Atticus Hainsworth, a neuroscientist at City St George’s, University of London, are cautiously optimistic. “It’s early days to say much definitively,” said Hainsworth, who was not involved in the Alzheimer’s study but is evaluating the AriBio drug for another brain condition, one affecting small blood vessels that is a common cause of stroke and dementia. But the evidence so far in people not taking other dementia drugs “looks pretty good to me,” he said.

领导此次试验的斯坦福大学记忆障碍中心主任、神经学家莎伦·沙(Sharon Sha)表示,如果低剂量配方的Mvix获批用于治疗阿尔茨海默病,它将成为美国首款获准用于减缓该疾病进展的口服药。

If approved for Alzheimer’s, the low-dose formulation of Mvix would be the first pill authorized in the United States to slow the disease, said Sharon Sha, a neurologist who directs the Stanford Center for Memory Disorders and led the trial.

现有疗法要么是在病情持续恶化的同时暂时缓解症状,要么是抗体疗法。这类抗体疗法减缓疾病的效果与Mvix在未服用其他痴呆症药物的试验参与者身上表现出的效果大致相当,但必须通过输液或注射给药,并带有脑肿胀和脑出血的风险。

Existing treatments either temporarily ease symptoms while the underlying decline continues unabated, or are antibody therapies that slow the disease about as much as Mvix did in trial participants not on other dementia drugs but must be given by infusion or injection and carry a risk of brain swelling and bleeding.

周一在阿尔茨海默病临床试验大会上公布研究结果的莎伦·沙表示:“因此,能有一种副作用相对极小、且为口服的疾病修正药物,意义将极其重大。这非常令人兴奋,也很有前景。”从卧室走向大脑,对Mvix来说将是绝佳的第二幕。毕竟,对伟哥及其化学同类药物而言,重塑并非新鲜事。

“So, to have a disease-modifying drug with relatively minimal side effects that is oral would be huge,” said Sha, who presented the findings Monday at the Clinical Trials on Alzheimer’s Disease conference. “It’s very exciting and promising.”A leap from the bedroom to the brain would be a fitting second act for Mvix. After all, reinvention is nothing new for Viagra and its chemical cousins.

这些药物的作用机制完全相同。它们会使一种名为磷酸二酯酶5型的酶失效,该酶通常会关闭促使血管放松的化学信号。由于这个“关闭开关”被卡住,信号得以持续,对于勃起功能障碍男性而言,这意味着在兴奋时会有更多血液涌入阴茎并滞留其中。

These drugs all work the same way. They disable an enzyme called phosphodiesterase type 5 that normally shuts off a chemical signal telling blood vessels to relax. With that off switch jammed, the signal lingers, which for men with erectile dysfunction means more blood can rush into the penis during arousal and stay there.

然而,同样的信号也在大脑中起作用,在那里它会打开一个神经细胞用来巩固彼此连接的分子开关,这是锁定记忆的关键一步。人们认为,如果让这个开关保持开启时间更长,受损的大脑可能会得到增强。

Yet that same signal also operates in the brain, where it flips on a molecular switch that nerve cells use to reinforce their connections, a key step in locking in memories. Keep it on longer, the thinking goes, and an ailing brain might get a boost.

正是这种血管效应首先吸引了研究人员的注意。20世纪90年代初,辉瑞公司测试了一种此类实验性药丸,用以治疗心绞痛——这是一种因流向心脏的血液不足而引起的胸痛。

It was the blood-vessel effect that first caught researchers’ attention. In the early 1990s, Pfizer tested an experimental pill of this kind as a treatment for angina, the chest pain caused by poor blood flow to the heart.

这种药物对心脏几乎没有作用。但在早期研究中,男性受试者报告了一个意想不到的副作用:勃起。美国食品药品监督管理局于1998年批准该药物为伟哥。

The drug did little for the heart. But men in early studies reported an unexpected side effect: erections. The FDA approved the drug as Viagra in 1998.

与大脑存在关联的最初迹象出现在后来,那是针对啮齿动物的研究,研究显示这类药物改善了为呈现阿尔茨海默病特征而培育的小鼠的记忆力。随后的医疗记录分析表明,这种效果可能会延续到人类身上。

The first hints of a link to the brain came later, from rodent studies in which the drugs improved memory in mice bred to develop features of Alzheimer’s disease. Analyses of medical records then suggested the effect might carry over to people.

一项针对700多万美国人医疗保险索赔的研究发现,服用伟哥的人在6年内患阿尔茨海默病的可能性降低了69%。另一项针对近27万名患有勃起功能障碍的英国男性的研究发现,在被开处方使用伟哥、西力士及类似疗法的人群中,风险降低了18%。

One study of insurance claims for more than 7 million Americans found that people taking Viagra were 69 percent less likely to develop Alzheimer’s over six years. Another study of nearly 270,000 British men with erectile dysfunction found an 18 percent lower risk among those prescribed Viagra, Cialis and similar therapies.

但这类研究无法证明因果关系。而且,并非该类药物中的所有药物在抵达大脑并锁定目标方面都同样出色。

But studies like these can’t prove cause and effect. And not all drugs in this class may be equally good at reaching the brain and finding their mark.

阿里比奥公司认为自己具有优势。实验室研究表明,该公司研发的药物在攻击其共同靶点时的精准度大约是伟哥的10倍,而且该公司表示,这种药物也更容易进入大脑。

AriBio thought it had an edge. Lab studies showed its drug was about 10 times as precise as Viagra at hitting its common target, and the company says it also gets into the brain more readily.

2022年底,阿里比奥公司开始在北美、欧洲和亚洲的记忆诊所测试其药丸。

In late 2022, AriBio began testing its pill in memory clinics across North America, Europe and Asia.

阿里比奥公司选择了每天30毫克的剂量,这不到多数男性治疗勃起功能障碍所用100毫克的三分之一。该公司推断,这个剂量足以对大脑起作用,同时又足够低,以避免产生可能会向参与者透露他们服用的是真药还是安慰剂的副作用。

AriBio chose a daily dose of 30 milligrams, less than a third of the 100 milligrams most men take for erectile dysfunction. That was enough to act on the brain, the company reasoned, but low enough to avoid side effects that might tip participants off to whether they were getting the real drug.

这场赌博似乎得到了回报。经过一年的治疗,未服用其他痴呆症药物的人病情进展更慢。对参与者脊髓液的检测显示,这种药物正在到达其在大脑中的目标。在未服用其他痴呆症药物的人群中,这种疗法降低了一种与疾病相关的Tau蛋白水平,该蛋白会导致阿尔茨海默病患者体内积聚毒性缠结。阿里生物(AriBio)治疗的副作用包括腹泻、头晕和昏厥。

The bet appears to have paid off. After a year of treatment, people who weren’t taking other dementia medications declined more slowly. Tests of participants’ spinal fluid showed that the drug was reaching its target in the brain. And among those not on other dementia drugs, the therapy lowered levels of a disease-linked form of tau, a protein that contributes to the toxic tangles that build up in Alzheimer’s. Side effects of the AriBio treatment included diarrhea, dizziness and fainting.

至于让伟哥成名的那个奇效呢?在大约770名服用该药的人中,只有三人报告性欲有所增强,这可能是因为剂量远低于用于治疗勃起功能障碍的剂量。

As for the quirk that made Viagra famous? Only three of the roughly 770 people taking the drug reported a boost in libido, perhaps because the dose was well below what’s used for erectile dysfunction.

还有那个悬在整个试验之上的谜团:为什么这种药丸只对那些没有服用其他痴呆症药物的人有帮助?沙说:“我们现在都有这个疑问。”

Then there’s the puzzle hanging over the whole trial: Why did the pill help only those who weren’t already on other dementia drugs? “We all have that question right now,” Sha said.

原因可能是该药丸的效果与标准痴呆症药物的效果重叠,从而留给额外益处的空间很小。或者,那些已经在服用这些药物的人可能更难被帮助,其中病情从极轻度发展为轻度痴呆的比例略高一些。

It could be that the pill’s effects overlap with those of standard dementia drugs, leaving little room for added benefit. Or people already taking those medications, a somewhat larger share of whom had progressed from very mild to mild dementia, may simply have been harder to help.

无论原因是什么,阿里生物现在都必须向监管机构陈述理由。该公司董事总经理金弗雷德(Fred Kim)表示:“主要目标已经达成。但它是否足以获批,还有待讨论。”

Whatever the reason, AriBio now has to make its case to regulators. “The primary objective was met,” said Fred Kim, the company’s managing director. “But whether it’s sufficient for approval is a matter of discussion.”

他说,如果有一条前进的道路,“我们会去争取。如果没有,那我们能怎么办?我们会拭目以待。”

If there’s a path forward, he said, “we’re going to go for it. If there isn’t, then what can we do? We’re going to find out.”

阅读媒体原文 ↗